- Record: found
- Abstract: found
- Article: not found
Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial.
Kristian Reich
1 ,
Frank O Nestle ,
Kim Papp ,
Jean-Paul Ortonne ,
Robert Evans ,
Cynthia Guzzo ,
Shu Li ,
Lisa T Dooley ,
Christopher E M Griffiths
October 18 2005
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Tumour necrosis factor alpha (TNFalpha) is thought to play a part in the pathogenesis of psoriasis. We assessed the efficacy and safety of continuous treatment with infliximab, a monoclonal antibody that binds to and neutralises the activity of TNFalpha, in patients with psoriasis.